{"disease":{"id":"mixed-phenotype-acute-leukemia-mpal","name":"mixed phenotype acute leukemia mpal"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07517510","title":"HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).","phase":"PHASE2","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":40,"lead_sponsor_name":"Guangdong Second Provincial General Hospital","has_results":false},{"nct_id":"NCT04501614","title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT04827745","title":"Blinatumomab for Treatment of R/R or MRD-positive CD19-Positive MPAL","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":2,"lead_sponsor_name":"University of Maryland, Baltimore","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}